Acurx Pharmaceuticals’ (ACXP) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Acurx Pharmaceuticals (NASDAQ:ACXP) in a research note issued to investors on Tuesday morning,Benzinga reports.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a research report on Friday, July 17th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold”.

Acurx Pharmaceuticals Price Performance

Shares of NASDAQ:ACXP opened at $1.26 on Tuesday. Acurx Pharmaceuticals has a 1-year low of $1.23 and a 1-year high of $8.34. The firm has a fifty day moving average price of $1.42 and a 200 day moving average price of $2.00. The stock has a market cap of $7.01 million, a P/E ratio of -0.47 and a beta of -2.05.

Acurx Pharmaceuticals (NASDAQ:ACXP) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.15). Sell-side analysts expect that Acurx Pharmaceuticals will post -2 EPS for the current fiscal year.

Acurx Pharmaceuticals Company Profile

Acurx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel antibiotics for serious bacterial infections. The company’s approach centers on targeting bacterial DNA polymerase IIIC, an enzyme required for the replication of certain bacteria and distinct from targets used by many existing antibiotics.

Acurx’s lead product candidate is ibezapolstat, an orally administered antibiotic being developed for the treatment of Clostridioides difficile infection, commonly known as C.